Combination strategies to enhance antitumor ADCC

Immunotherapy

Volumn 4, Issue 5, 2012, Pages 511-527

  Kohrt, Holbrook E ^a   Houot, Roch ^b,c   Marabelle, Aurélien ^a   Cho, Hearn Jay ^d   Osman, Keren ^d   Goldstein, Matthew ^a   Levy, Ronald ^a   Brody, Joshua ^d  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RENNES UNIVERSITY HOSPITAL   (France)

^c INSERM   (France)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

T cells; ADCC; cancer; cytokines; IMiD; immunocytokines; immunomodulators; interleukins; monoclonal antibodies; NK cells; passive immunotherapy

Indexed keywords

ALEMTUZUMAB; CD16 ANTIGEN; CD20 ANTIGEN; CD8 ANTIGEN; CETUXIMAB; CPG OLIGODEOXYNUCLEOTIDE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FC RECEPTOR; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 2; LENALIDOMIDE; MONOCLONAL ANTIBODY; NATURAL KILLER CELL RECEPTOR NKG2D; NIVOLUMAB; OBINUTUZUMAB; OFATUMUMAB; PANITUMUMAB; PREDNISONE; RITUXIMAB; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TRASTUZUMAB; TRX 518; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ADOPTIVE TRANSFER; ADVANCED CANCER; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; B LYMPHOCYTE; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; CYTOKINE RELEASE; DENDRITIC CELL; DRUG EFFICACY; EFFECTOR CELL; FEASIBILITY STUDY; FOLLICULAR LYMPHOMA; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; INNATE IMMUNITY; LARGE CELL LYMPHOMA; LYMPHOKINE ACTIVATED KILLER CELL; LYMPHOMA; MACROPHAGE; MOUTH CANCER; MULTIPLE MYELOMA; NATURAL KILLER CELL; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OROPHARYNX CANCER; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; COMBINED MODALITY THERAPY; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; NEOPLASMS;

EID: 84861697886     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.38     Document Type: Review

References (205)

1. Houot R, Kohrt H, Goldstein MJ, Levy R. Immunomodulating antibodies and drugs for the treatment of hematological malignancies. Cancer Metastasis Rev. 30(1), 97-109 (2011).
2. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 6(4), 443-446 (2000).
3. Haynes NM, Hawkins ED, Li M et al. CD11c dendritic cells and B cells contribute to the tumoricidal activity of anti-DR5 antibody therapy in established tumors. J. Immunol. 185(1), 532-541 (2010).
4. Marquez ME, Millet C, Stekman H et al. CD16 cross-linking induces increased expression of CD56 and production of IL 12 in peripheral NK cells. Cell. Immunol. 264(1), 86-92 (2010).
5. Walzer T, Dalod M, Vivier E, Zitvogel L. Natural killer cell-dendritic cell crosstalk in the initiation of immune responses. Expert Opin Biol. Ther. 5(Suppl. 1), S49-S59 (2005).
6. Cartron G, Dacheux L, Salles G et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgRIIIa gene. Blood 99(3), 754-758 (2002).
7. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21(21), 3940-3947 (2003).
8. Musolino A, Naldi N, Bortesi B et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER 2/neu-positive metastatic breast cancer. J. Clin. Oncol. 26(11), 1789-1796 (2008).
9. Zhang W, Gordon M, Schultheis AM et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-Agent cetuximab. J. Clin. Oncol. 25(24), 3712-3718 (2007).
10. Bibeau F, Lopez-Crapez E, Di Fiore F et al. Impact of Fc{g}RIIa-Fc{g}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J. Clin. Oncol. 27(7), 1122-1129 (2009).
11. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 10(5), 317-327 (2010).
12. Wierda WG, Kipps TJ, Mayer J et al. Ofatumumab as single-Agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J. Clin. Oncol. 28(10), 1749-1755 (2010).
13. Sehn LH, Goy A, Offner FC et al. Randomized Phase II trial comparing GA101 (obinutuzumab) with rituximab in patients with relapsed CD20 indolent B cell non-Hodgkin lymphoma: Preliminary analysis of the GAUSS study. Presented at: 53rd ASH Annual Meeting and Exposition. San Diego, CA, USA, 10-13 December 2011 (Abstract 269).
14. Robak T, Robak E. New anti-CD20 monoclonal antibodies for the treatment of B cell lymphoid malignancies. BioDrugs 25(1), 13-25 (2011).
15. Van Meerten T, Hagenbeek A. CD20-targeted therapy: The next generation of antibodies. Semin. Hematol. 47(2), 199-210 (2010).
16. Prevodnik VK, Lavrencak J, Horvat M, Novakovic BJ. The predictive significance of CD20 expression in B cell lymphomas. Diagn. Pathol. 6, 33 (2011).
17. Sivaraman S, Deshpande CG, Ranganathan R et al. Tumor necrosis factor modulates CD 20 expression on cells from chronic lymphocytic leukemia: A new role for TNF a? Microsc. Res. Tech. 50(3), 251-257 (2000).
18. Kunala S, Macklis RM. Ionizing radiation induces CD20 surface expression on human B cells. Int. J. Cancer 96(3), 178-181 (2001).
19. Dahl M, Bouchelouche P, Kramer-Marek G, Capala J, Nordling J, Bouchelouche K. Sarcosine induces increase in HER2/neu expression in androgen-dependent prostate cancer cells. Mol. Biol. Rep. 38(7), 4237-4243 (2011).
20. Takenouchi M, Hirai S, Sakuragi N, Yagita H, Hamada H, Kato K. Epigenetic modulation enhances the therapeutic effect of anti-IL 13R(a)2 antibody in human mesothelioma xenografts. Clin. Cancer Res. 17(9), 2819-2829 (2011).
21. Mankai A, Buhe V, Hammadi M et al. Improvement of rituximab efficiency in chronic lymphocytic leukemia by CpG-mediated upregulation of CD20 expression independently of PU.1. Ann. NY Acad. Sci. 1173, 721-728 (2009).
22. Decker T, Schneller F, Sparwasser T et al. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood 95(3), 999-1006 (2000).
23. Jahrsdorfer B, Hartmann G, Racila E et al. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J. Leukoc. Biol. 69(1), 81-88 (2001).
24. Friedberg JW, Kelly JL, Neuberg D et al. Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. Br. J. Haematol. 146(3), 282-291 (2009).
25. Friedberg JW, Kim H, McCauley M et al. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: Increased interferon a/b-inducible gene expression, without significant toxicity. Blood 105(2), 489-495 (2005).
26. Leonard JP, Link BK, Emmanouilides C et al. Phase I trial of Toll-like receptor 9 agonist PF 3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. Clin. Cancer Res. 13(20), 6168-6174 (2007).
27. Zent CS, Smith BJ, Ballas ZK et al. Phase I clinical trial of CpG oligonucleotide 7909 (PF 03512676) in patients with previously treated chronic lymphocytic leukemia. Leuk. Lymphoma 53(2), 211-217 (2011).
28. Schultz KR, Klarnet JP, Peace DJ et al. Monoclonal antibody therapy of murine lymphoma: Enhanced efficacy by concurrent administration of interleukin 2 or lymphokine-Activated killer cells. Cancer Res. 50(17), 5421-5425 (1990).
29. Senba T, Kuroki M, Arakawa F et al. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-Activated killer cells in vitro and in SCID mouse xenograft model. Anticancer Res. 18(1A), 17-24 (1998).
30. Watanabe M, Kubota T, Kitajima M, Hakomori S. Synergetic effect of interleukin 2 and cellular cytotoxicity against a novel tumor-Associated carbohydrate antigen Le(a)/Le(a) (dimeric Le(a)) mediated by monoclonal antibody NCC ST 421 in adoptive immunization using SCID mice. Cancer Immunol. Immunother. 37(4), 245-250 (1993).
31. Berdeja JG, Hess A, Lucas DM et al. Systemic interleukin 2 and adoptive transfer of lymphokine-Activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B cell lymphoma treated with rituximab. Clin. Cancer Res. 13(8), 2392-2399 (2007).
32. Gomes AQ, Martins DS, Silva-Santos B. Targeting gd T lymphocytes for cancer immunotherapy: From novel mechanistic insight to clinical application. Cancer Res. 70(24), 10024-10027 (2010).
33. Kabelitz D, Wesch D, He W. Perspectives of gd T cells in tumor immunology. Cancer Res. 67(1), 5-8 (2007).
34. Ma Y, Aymeric L, Locher C et al. Contribution of IL 17-producing g d T cells to the efficacy of anticancer chemotherapy. J. Exp. Med. 208(3), 491-503 (2011).
35. Godder KT, Henslee-Downey PJ, Mehta J et al. Long term disease-free survival in acute leukemia patients recovering with increased gd T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant. 39(12), 751-757 (2007).
36. Angelini DF, Borsellino G, Poupot M et al. FcgRIII discriminates between 2 subsets of Vg9Vd2 effector cells with different responses and activation pathways. Blood 104(6), 1801-1807 (2004).
37. Lafont V, Liautard J, Liautard JP, Favero J. Production of TNF a by human V g 9V d 2 T cells via engagement of Fc g RIIIA, the low affinity type 3 receptor for the Fc portion of IgG, expressed upon TCR activation by nonpeptidic antigen. J. Immunol. 166(12), 7190-7199 (2001).
38. Braza MS, Klein B, Fiol G, Rossi JF. gd T cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody. Haematologica 96(3), 400-407 (2011).
39. Gertner-Dardenne J, Bonnafous C, Bezombes C et al. Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies. Blood 113(20), 4875-4884 (2009).
40. Tokuyama H, Hagi T, Mattarollo SR et al. V g 9 V d 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs - rituximab and trastuzumab. Int. J. Cancer 122(11), 2526-2534 (2008).
41. Maniar A, Zhang X, Lin W et al. Human gd T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement. Blood 116(10), 1726-1733 (2010).
42. Kohrt HE, Houot R, Goldstein MJ et al. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 117(8), 2423-2432 (2011).
43. Lamb LS, Lopez RD. gd T cells: A new frontier for immunotherapy? Biol. Blood Marrow Transplant. 11(3), 161-168 (2005).
44. Salot S, Laplace C, Saiagh S et al. Large scale expansion of g 9 d 2 T lymphocytes: Innacell g d cell therapy product. J. Immunol. Methods 326(1-2), 63-75 (2007).
45. Hayday AC. [g][d] cells: A right time and a right place for a conserved third way of protection. Annu. Rev. Immunol. 18, 975-1026 (2000).
46. Bennouna J, Bompas E, Neidhardt EM et al. Phase I study of Innacell gd, an autologous cell-therapy product highly enriched in g9d2 T lymphocytes, in combination with IL 2, in patients with metastatic renal cell carcinoma. Cancer Immunol. Immunother. 57(11), 1599-1609 (2008).
47. Dieli F, Vermijlen D, Fulfaro F et al. Targeting human {g}d} T cells with zoledronate and interleukin 2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res. 67(15), 7450-7457 (2007).
48. Kobayashi H, Tanaka Y, Yagi J et al. Safety profile and anti-tumor effects of adoptive immunotherapy using g d T cells against advanced renal cell carcinoma: A pilot study. Cancer Immunol. Immunother. 56(4), 469-476 (2007).
49. Meraviglia S, Eberl M, Vermijlen D et al. In vivo manipulation of Vg9Vd2 T cells with zoledronate and low-dose interleukin 2 for immunotherapy of advanced breast cancer patients. Clin. Exp. Immunol. 161(2), 290-297 (2010).
50. Nakajima J, Murakawa T, Fukami T et al. A Phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous gd T cells. Eur. J. Cardiothorac. Surg. 37(5), 1191-1197 (2010).
51. Nicol AJ, Tokuyama H, Mattarollo SR et al. Clinical evaluation of autologous g d T cell-based immunotherapy for metastatic solid tumours. Br. J. Cancer 105(6), 778-786 (2011).
52. Wilhelm M, Kunzmann V, Eckstein S et al. gd T cells for immune therapy of patients with lymphoid malignancies. Blood 102(1), 200-206 (2003).
53. Jahrsdorfer B, Weiner GJ. Immunostimulatory CpG oligodeoxynucleotides and antibody therapy of cancer. Semin. Oncol. 30(4), 476-482 (2003).
54. Moga E, Alvarez E, Canto E et al. NK cells stimulated with IL 15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B cell lymphoma. Exp. Hematol. 36(1), 69-77 (2008).
55. Betting DJ, Yamada RE, Kafi K, Said J, Van Rooijen N, Timmerman JM. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma. J. Immunother. 32(6), 622-631 (2009).
56. Wooldridge JE, Ballas Z, Krieg AM, Weiner GJ. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood 89(8), 2994-2998 (1997).
57. Wang H, Rayburn ER, Wang W, Kandimalla ER, Agrawal S, Zhang R. Immunomodulatory oligonucleotides as novel therapy for breast cancer: Pharmacokinetics, in vitro and in vivo anticancer activity, and potentiation of antibody therapy. Mol. Cancer Ther. 5(8), 2106-2114 (2006).
58. Van Ojik HH, Bevaart L, Dahle CE et al. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations. Cancer Res. 63(17), 5595-5600 (2003).
59. Roda JM, Parihar R, Carson WE 3rd. CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells. J. Immunol. 175(3), 1619-1627 (2005).
60. Rosa R, Melisi D, Damiano V et al. Toll-like receptor 9 agonist IMO cooperates with cetuximab in K ras mutant colorectal and pancreatic cancers. Clin. Cancer Res. 17(20), 6531-6541 (2011).
61. Damiano V, Garofalo S, Rosa R et al. A novel Toll-like receptor 9 agonist cooperates with trastuzumab in trastuzumab-resistant breast tumors through multiple mechanisms of action. Clin. Cancer Res. 15(22), 6921-6930 (2009).
62. Lu H, Yang Y, Gad E et al. TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy. Clin. Cancer Res. 17(21), 6742-6753 (2011).
63. Nicodemus CF, Wang L, Lucas J, Varghese B, Berek JS. Toll-like receptor 3 as a target to enhance bioactivity of cancer immunotherapy. Am. J. Obstet. Gynecol. 202(6), 608.e1-8 (2010).
64. Wang S, Astsaturov IA, Bingham CA et al. Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment. Cancer Immunol. Immunother. 61(1), 49-61 (2012).
65. Hamm S, Rath S, Michel S, Baumgartner R. Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists. J. Immunotoxicol. 6(4), 257-265 (2009).
66. Lu H, Dietsch GN, Matthews MA et al. VTX 2337 is a novel TLR8 agonist that activates NK cells and augments ADCC. Clin. Cancer Res. 18(2), 499-509 (2012).
67. Zoglmeier C, Bauer H, Norenberg D et al. CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice. Clin. Cancer Res. 17(7), 1765-1775 (2011).
68. Wu L, Adams M, Carter T et al. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20 tumor cells. Clin. Cancer Res. 14(14), 4650-4657 (2008).
69. Wu L, Parton A, Lu L, Adams M, Schafer P, Bartlett JB. Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: Influence of host immune and tumor markers. Cancer Immunol. Immunother. 60(1), 61-73 (2011).
70. Reddy N, Hernandez-Ilizaliturri FJ, Deeb G et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br. J. Haematol. 140(1), 36-45 (2008).
71. Hayashi T, Hideshima T, Akiyama M et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: Clinical application. Br. J. Haematol. 128(2), 192-203 (2005).
72. Berg SL, Cairo MS, Russell H et al. Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: A children's oncology group Phase I consortium report. J. Clin. Oncol. 29(3), 316-323 (2011).
73. Zinzani PL, Pellegrini C, Gandolfi L et al. Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B cell lymphoma: A Phase 2 trial. Clin. Lymphoma Myeloma Leuk. 11(6), 462-466 (2011).
74. Nowakowski GS, Laplant B, Habermann TM et al. Lenalidomide can be safely combined with R CHOP (R2CHOP) in the initial chemotherapy for aggressive B cell lymphomas: Phase I study. Leukemia 25(12), 1877-1881 (2011).
75. Brown JR, Abramson J, Hochberg E et al. A Phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL. Leukemia 24(11), 1972-1975 (2010).
76. Fowler N, Hagemeister F, Mclaughlin P et al. High response rates with lenalidomide plus rituximab for untreated indolent B cell non-Hodgkins lymphoma. Ann. Oncol. 22(Suppl. 4), iv128-iv129 (2011).
77. Witzig TE, Wiernik PH, Moore T et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's lymphoma. J. Clin. Oncol. 27(32), 5404-5409 (2009).
78. Hainsworth JD, Litchy S, Burris HA 3rd et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J. Clin. Oncol. 20(20), 4261-4267 (2002).
79. Lanier LL. Up on the tightrope: Natural killer cell activation and inhibition. Nat. Immunol. 9(5), 495-502 (2008).
80. Inagaki A, Ishida T, Yano H et al. Expression of the ULBP ligands for NKG2D by B NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC. Int. J. Cancer 125(1), 212-221 (2009).
81. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413(6852), 165-171 (2001).
82. Sutherland CL, Rabinovich B, Chalupny NJ, Brawand P, Miller R, Cosman D. ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL 15. Blood 108(4), 1313-1319 (2006).
83. Zhang C, Niu J, Zhang J, Wang Y, Zhou Z, Tian Z. Opposing effects of interferon a and interferon g on the expression of major histocompatibility complex class I chain-related A in tumors. Cancer Sci. 99(6), 1279-1286 (2008).
84. Poggi A, Catellani S, Garuti A, Pierri I, Gobbi M, Zocchi MR. Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate. Leukemia 23(4), 641-648 (2009).
85. Lu X, Ohata K, Kondo Y, Espinoza JL, Qi Z, Nakao S. Hydroxyurea upregulates NKG2D ligand expression in myeloid leukemia cells synergistically with valproic acid and potentially enhances susceptibility of leukemic cells to natural killer cell-mediated cytolysis. Cancer Sci. 101(3), 609-615 (2010).
86. Vales-Gomez M, Chisholm SE, Cassady-Cain RL, Roda-Navarro P, Reyburn HT. Selective induction of expression of a ligand for the NKG2D receptor by proteasome inhibitors. Cancer Res. 68(5), 1546-1554 (2008).
87. Kato N, Tanaka J, Sugita J et al. Regulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells. Leukemia 21(10), 2103-2108 (2007).
88. Diermayr S, Himmelreich H, Durovic B et al. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. Blood 111(3), 1428-1436 (2008).
89. Shimizu R, Kikuchi J, Wada T, Ozawa K, Kano Y, Furukawa Y. HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells. Leukemia 24(10), 1760-1768 (2010).
90. Huang X, Wang S, Lee CK, Yang X, Liu B. HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance. Cancer Lett. 307(1), 72-79 (2011).
91. Blum KA, Advani A, Fernandez L et al. Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia. Br. J. Haematol. 147(4), 507-514 (2009).
92. Masucci G, Wersall P, Ragnhammar P, Mellstedt H. Granulocyte-monocyte- colony-stimulating factor augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity. Cancer Immunol. Immunother. 29(4), 288-292 (1989).
93. Ragnhammar P, Frodin JE, Trotta PP, Mellstedt H. Cytotoxicity of white blood cells activated by granulocyte-colony-stimulating factor, granulocyte/macrophage-colony-stimulating factor and macrophage-colony- stimulating factor against tumor cells in the presence of various monoclonal antibodies. Cancer Immunol. Immunother. 39(4), 254-262 (1994).
94. Burgess AW, Begley CG, Johnson GR et al. Purification and properties of bacterially synthesized human granulocyte-macrophage colony stimulating factor. Blood 69(1), 43-51 (1987).
95. Charak BS, Agah R, Mazumder A. Granulocyte-macrophage colony-stimulating factor-induced antibody-dependent cellular cytotoxicity in bone marrow macrophages: Application in bone marrow transplantation. Blood 81(12), 3474-3479 (1993).
96. Venugopal P, Sivaraman S, Huang XK, Nayini J, Gregory SA, Preisler HD. Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia. Leuk. Res. 24(5), 411-415 (2000).
97. Ragnhammar P, Masucci G, Frodin JE, Hjelm AL, Mellstedt H. Cytotoxic functions of blood mononuclear cells in patients with colorectal carcinoma treated with mAb 17 1A and granulocyte/macrophage-colony-stimulating factor. Cancer Immunol. Immunother. 35(3), 158-164 (1992).
98. Liljefors M, Nilsson B, Mellstedt H, Frodin JE. Influence of varying doses of granulocyte-macrophage colony-stimulating factor on pharmacokinetics and antibody-dependent cellular cytotoxicity. Cancer Immunol. Immunother. 57(3), 379-388 (2008).
99. Morales JK, Kmieciak M, Knutson KL, Bear HD, Manjili MH. GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells. Breast Cancer Res. Treat. 123(1), 39-49 (2010).
100. Li H, Han Y, Guo Q, Zhang M, Cao X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF b 1. J. Immunol. 182(1), 240-249 (2009).
101. Biron CA, Sonnenfeld G, Welsh RM. Interferon induces natural killer cell blastogenesis in vivo. J. Leukoc. Biol. 35(1), 31-37 (1984).
102. Nguyen KB, Salazar-Mather TP, Dalod MY et al. Coordinated and distinct roles for IFN a b, IL 12, and IL 15 regulation of NK cell responses to viral infection. J. Immunol. 169(8), 4279-4287 (2002).
103. Masucci MG, Szigeti R, Klein E et al. Effect of interferon a 1 from E. coli on some cell functions. Science 209(4463), 1431-1435 (1980).
104. Yano H, Ishida T, Inagaki A et al. Defucosylated anti CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: A novel immunotherapy for aggressive/refractory mycosis fungoides and sezary syndrome. Clin. Cancer Res. 13(21), 6494-6500 (2007).
105. Bungard S, Flieger D, Schweitzer S, Sauerbruch T, Spengler U. The combination of interleukin 2 and interferon a effectively augments the antibody-dependent cellular cytotoxicity of monoclonal antibodies 17 1A and BR55-2 against the colorectal carcinoma cell line HT29. Cancer Immunol. Immunother. 46(4), 213-220 (1998).
106. Mukhopadhyaya R, Tatake RJ, Krishnan N et al. Immunoreactivity of lymphocytes from draining lymph nodes, peripheral blood and tumor infiltrates from oral cancer patients. J. Clin. Lab. Immunol. 30(1), 21-25 (1989).
107. Fehr HG, Fan S, Lotzerich H, Appell HJ. Cytokine stimulation of antibody-dependent cellular cytotoxicity (ADCC) enhances cytolytic but not binding capacity of peritoneal macrophages. Anticancer Res. 10(3), 821-825 (1990).
108. Eisenthal A, Cameron RB, Rosenberg SA. Induction of antibody-dependent cellular cytotoxicity in vivo by IFN a and its antitumor efficacy against established B16 melanoma liver metastases when combined with specific anti-B16 monoclonal antibody. J. Immunol. 144(11), 4463-4471 (1990).
109. Ozer H, Gavigan M, O'Malley J et al. Immunomodulation by recombinant interferon a 2 in a Phase I trial in patients with lymphoproliferative malignancies. J. Biol. Response Mod. 2(6), 499-515 (1983).
110. Sivaraman S, Venugopal P, Ranganathan R et al. Effect of interferon a on CD20 antigen expression of B cell chronic lymphocytic leukemia. Cytokines Cell. Mol. Ther. 6(2), 81-87 (2000).
111. Portlock CS, O'Connor OA, Straus DJ et al. Pegylated interferon plus rituximab in advanced stage, indolent lymphoma: Is there CD20 antigen upregulation? Leuk. Lymphoma 47(7), 1260-1264 (2006).
112. Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193(4257), 1007-1008 (1976).
113. Smith KA. Interleukin 2: Inception, impact, and implications. Science 240(4856), 1169-1176 (1988).
114. Tsudo M, Goldman CK, Bongiovanni KF et al. The p75 peptide is the receptor for interleukin 2 expressed on large granular lymphocytes and is responsible for the interleukin 2 activation of these cells. Proc. Natl Acad. Sci. USA 84(15), 5394-5398 (1987).
115. Caligiuri MA, Zmuidzinas A, Manley TJ, Levine H, Smith KA, Ritz J. Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. J. Exp. Med. 171(5), 1509-1526 (1990).
116. Gluck WL, Hurst D, Yuen A et al. Phase I studies of interleukin (IL)-2 and rituximab in B cell non-Hodgkin's lymphoma: IL 2 mediated natural killer cell expansion correlations with clinical response. Clin. Cancer Res. 10(7), 2253-2264 (2004).
117. Hooijberg E, Sein JJ, Van Den Berk PC et al. Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2. Cancer Res. 55(12), 2627-2634 (1995).
118. Sondel PM, Hank JA. Combination therapy with interleukin 2 and antitumor monoclonal antibodies. Cancer J. Sci. Am. 3(Suppl. 1), S121-S127 (1997).
119. Yu AL, Gilman AL, Ozkaynak MF et al. Anti-GD2 antibody with GM-CSF, interleukin 2, and isotretinoin for neuroblastoma. N. Engl. J. Med. 363(14), 1324-1334 (2010).
120. Colombo MP, Trinchieri G. Interleukin 12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13(2), 155-168 (2002).
121. Trinchieri G. Interleukin 12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. 3(2), 133-146 (2003).
122. Parihar R, Dierksheide J, Hu Y, Carson WE. IL 12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. J. Clin. Invest. 110(7), 983-992 (2002).
123. Jaime-Ramirez AC, Mundy-Bosse BL, Kondadasula S et al. IL 12 enhances the antitumor actions of trastuzumab via NK cell IFN g production. J. Immunol. 186(6), 3401-3409 (2011).
124. Jacobson NG, Szabo SJ, Weber-Nordt RM et al. Interleukin 12 signaling in T helper type 1 (Th1) cells involves tyrosine phosphorylation of signal transducer and activator of transcription (Stat)3 and Stat4. J. Exp. Med. 181(5), 1755-1762 (1995).
125. Nimmerjahn F, Ravetch JV. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310(5753), 1510-1512 (2005).
126. Farag SS, Caligiuri MA. Human natural killer cell development and biology. Blood Rev. 20(3), 123-137 (2006).
127. 34+ hematopoietic progenitor cells. Blood 87(7), 2632-2640 (1996).
128. Fehniger TA, Caligiuri MA. Interleukin 15: Biology and relevance to human disease. Blood 97(1), 14-32 (2001).
129. Moga E, Canto E, Vidal S, Juarez C, Sierra J, Briones J. Interleukin 15 enhances rituximab-dependent cytotoxicity against chronic lymphocytic leukemia cells and overcomes transforming growth factor b-mediated immunosuppression. Exp. Hematol. 39(11), 1064-1071 (2011).
130. Roberti MP, Barrio MM, Bravo AI et al. IL 15 and IL 2 increase cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR. Breast Cancer Res. Treat. 130(2), 465-475 (2011).
131. Ben Ahmed M, Belhadj Hmida N, Moes N et al. IL 15 renders conventional lymphocytes resistant to suppressive functions of regulatory T cells through activation of the phosphatidylinositol 3-kinase pathway. J. Immunol. 182(11), 6763-6770 (2009).
132. Frederiksen KS, Lundsgaard D, Freeman JA et al. IL 21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunol. Immunother. 57(10), 1439-1449 (2008).
133. Davis ID, Skak K, Smyth MJ, Kristjansen PE, Miller DM, Sivakumar PV. Interleukin 21 signaling: Functions in cancer and autoimmunity. Clin. Cancer Res. 13(23), 6926-6932 (2007).
134. Watanabe M, Kono K, Kawaguchi Y et al. Interleukin 21 can efficiently restore impaired antibody-dependent cell-mediated cytotoxicity in patients with oesophageal squamous cell carcinoma. Br. J. Cancer 102(3), 520-529 (2010).
135. Roda JM, Joshi T, Butchar JP et al. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clin. Cancer Res. 13(21), 6419-6428 (2007).
136. Eskelund CW, Nederby L, Thysen AH, Skovbo A, Roug AS, Hokland ME. Interleukin 21 and rituximab enhance NK cell functionality in patients with B cell chronic lymphocytic leukaemia. Leuk. Res. 35(7), 914-920 (2011).
137. Smyth MJ, Teng MW, Sharkey J et al. Interleukin 21 enhances antibody-mediated tumor rejection. Cancer Res. 68(8), 3019-3025 (2008).
138. Timmerman JM, Byrd JC, Andorsky DJ et al. Efficacy and safety of recombinant interleukin 21 (rIL 21) and rituximab in relapsed/refractory indolent lymphoma. Presented at: ASCO 2008 Annual Meeting. Chicago, IL, USA, 30 May-3 June 2008 (Abstract 8554).
139. Shusterman S, London WB, Gillies SD et al. Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: A Children's Oncology Group (COG) Phase II study. J. Clin. Oncol. 28(33), 4969-4975 (2010).
140. Delgado DC, Hank JA, Kolesar J et al. Genotypes of NK cell KIR receptors, their ligands, and Fcg receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res. 70(23), 9554-9561 (2010).
141. Ribas A, Kirkwood JM, Atkins MB et al. Phase I/II open-label study of the biologic effects of the interleukin 2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma. J. Transl Med. 7, 68 (2009).
142. Gillies SD, Lan Y, Williams S et al. An anti-CD20-IL 2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma. Blood 105(10), 3972-3978 (2005).
143. Singh H, Serrano LM, Pfeiffer T et al. Combining adoptive cellular and immunocytokine therapies to improve treatment of B-lineage malignancy. Cancer Res. 67(6), 2872-2880 (2007).
144. Johannsen M, Spitaleri G, Curigliano G et al. The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, Phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. Eur. J. Cancer 46(16), 2926-2935 (2010).
145. Eigentler TK, Weide B, De Braud F et al. A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma. Clin. Cancer Res. 17(24), 7732-7742 (2011).
146. De Braud FG, Catania C, Onofri A et al. Combination of the immunocytokine F16-IL2 with doxorubicin or paclitaxel in patients with solid tumors: Results from two Phase Ib trials. J. Clin. Oncol. 28(Suppl. 15), e13017 (2011).
147. Davis CB, Gillies SD. Immunocytokines: Amplification of anti-cancer immunity. Cancer Immunol. Immunother. 52(5), 297-308 (2003).
148. Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Chang CH. CD20-targeted tetrameric interferon a, a novel and potent immunocytokine for the therapy of B cell lymphomas. Blood 114(18), 3864-3871 (2009).
149. Sharma S, Dominguez AL, Manrique SZ, Cavallo F, Sakaguchi S, Lustgarten J. Systemic targeting of CpG-ODN to the tumor microenvironment with anti-neu-CpG hybrid molecule and T regulatory cell depletion induces memory responses in BALB-neuT tolerant mice. Cancer Res. 68(18), 7530-7540 (2008).
150. Lin W, Voskens CJ, Zhang X et al. Fc-dependent expression of CD137 on human NK cells: Insights into 'agonistic' effects of anti-CD137 monoclonal antibodies. Blood 112(3), 699-707 (2008).
151. Melero I, Johnston JV, Shufford WW, Mittler RS, Chen L. NK1.1 cells express 4 1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4 1BB monoclonal antibodies. Cell. Immunol. 190(2), 167-172 (1998).
152. Wilcox RA, Tamada K, Strome SE, Chen L. Signaling through NK cell-Associated CD137 promotes both helper function for CD8 cytolytic T cells and responsiveness to IL 2 but not cytolytic activity. J. Immunol. 169(8), 4230-4236 (2002).
153. Stagg J, Loi S, Divisekera U et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc. Natl Acad. Sci. USA 108(17), 7142-7147 (2011).
154. Meseck M, Huang T, Ma G, Wang G, Chen SH, Woo SL. A functional
155. Croft M. Control of immunity by the TNFR-related molecule OX40 (CD134). Annu. Rev. Immunol. 28, 57-78 (2010).
156. Ogasawara K, Yoshinaga SK, Lanier LL. Inducible costimulator costimulates cytotoxic activity and IFN g production in activated murine NK cells. J. Immunol. 169(7), 3676-3685 (2002).
157. Lanier LL, Corliss B, Phillips JH. Arousal and inhibition of human NK cells. Immunol. Rev. 155, 145-154 (1997).
158. Funakoshi S, Longo DL, Murphy WJ. Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B cell lymphomas. J. Immunother. Emphasis Tumor Immunol. 19(2), 93-101 (1996).
159. Gennari R, Menard S, Fagnoni F et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin. Cancer Res. 10(17), 5650-5655 (2004).
160. Marechal R, De Schutter J, Nagy N et al. Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients. BMC Cancer 10, 340 (2010).
161. Borgerding A, Hasenkamp J, Engelke M et al. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression. Exp. Hematol. 38(3), 213-221 (2010).
162. Binstadt BA, Brumbaugh KM, Dick CJ et al. Sequential involvement of Lck and SHP 1 with MHC-recognizing receptors on NK cells inhibits FcR-initiated tyrosine kinase activation. Immunity 5(6), 629-638 (1996).
163. Leibson PJ. Signal transduction during natural killer cell activation: Inside the mind of a killer. Immunity 6(6), 655-661 (1997).
164. Koh CY, Blazar BR, George T et al. Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo. Blood 97(10), 3132-3137 (2001).
165. Romagne F, Andre P, Spee P et al. Preclinical characterization of 1 7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood 114(13), 2667-2677 (2009).
166. Srivastava S. Enhancing natural killer (NK) cell mediated killing of non-Hodgkin's lymphoma. Blood 114, Abstract 2706 (2009).
167. Binyamin L, Alpaugh RK, Hughes TL, Lutz CT, Campbell KS, Weiner LM. Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in -rfaut model of anti-lymphoma therapy. J. Immunol. 180(9), 6392-6401 (2008).
168. Nijhof IS, De Weers M, Andre P et al. Synergistic action of the human inhibitory KIR antibody IPH2102, and the human CD38 antibody daratumumab to enhance the lysis of primary multiple myeloma (MM) cells in the bone marrow mononuclear cells (MNCs) from myeloma patients. Presented at: 53rd ASH Annual Meeting and Exposition. San Diego, CA, USA, 10-13 December 2011 (Abstract 1865).
169. Buechele C, Baessler T, Wirths S, Schmohl JU, Schmiedel BJ, Salih HR. Glucocorticoid-induced TNFR-related protein (GITR) ligand modulates cytokine release and NK cell reactivity in chronic lymphocytic leukemia (CLL). Leukemia doi:10.1038/leu.2011.313. (2011) (Epub ahead of print).
170. Baltz KM, Krusch M, Bringmann A et al. Cancer immunoediting by GITR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell/tumor cell interactions. FASEB J. 21(10), 2442-2454 (2007).
171. Rosenzweig M, Ponte J, Apostolou I et al. Development of TRX518, an aglycosyl humanized monoclonal antibody (Mab) agonist of huGITR. Presented at: ASCO 2010 Annual Meeting. Chicago, IL, USA, 4-8 June 2010 (Abstract e13028).
172. Brown EJ, Frazier WA. Integrin-Associated protein (CD47) and its ligands. Trends Cell Biol. 11(3), 130-135 (2001).
173. Manches O, Lui G, Chaperot L et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 101(3), 949-954 (2003).
174. Uchida J, Hamaguchi Y, Oliver JA et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. 199(12), 1659-1669 (2004).
175. Tamura K, Shimizu C, Hojo T et al. Fc{g} R2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer. Ann. Oncol. 22(6), 1302-1307 (2011).
176. Jaiswal S, Chao MP, Majeti R, Weissman IL. Macrophages as mediators of tumor immunosurveillance. Trends Immunol. 31(6), 212-219 (2010).
177. Chao MP, Alizadeh AA, Tang C et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142(5), 699-713 (2010).
178. Ysebaert L, Laprevotte E, Klein C et al. 'Don't eat me': CD47 and LFA-1 modulate CLL response to nurselike cells-mediated antibody-dependent phagocytosis induced by rituximab and obinutuzumab (GA101). Presented at: 53rd ASH Annual Meeting and Exposition. San Diego, CA, USA, 10-13 December 2011 (Abstract 1762).
179. Benson DM, Bakan CE, Mishra A et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: A therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 116(13), 2286-2294 (2010).
180. Hodi FS, O'Day SJ, Mcdermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010).
181. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364(26), 2517-2526 (2011).
182. Sacchi S, Federico M, Vitolo U et al. Clinical activity and safety of combination immunotherapy with IFN a 2a and rituximab in patients with relapsed low grade non-Hodgkin's lymphoma. Haematologica 86(9), 951-958 (2001).
183. Davis TA, Maloney DG, Grillo-Lopez AJ et al. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon a-2a. Clin. Cancer Res. 6(7), 2644-2652 (2000).
184. Kimby E, Jurlander J, Geisler C et al. Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon a 2a: A randomized Phase II study from the Nordic lymphoma group. Leuk. Lymphoma 49(1), 102-112 (2008).
185. Cartron G, Zhao-Yang L, Baudard M et al. Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: Results of a Phase II study. J. Clin. Oncol. 26(16), 2725-2731 (2008).
186. Karmali R, Larson ML, Wooldridge JE et al. Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B cell lymphoma and mantle cell lymphoma. Leuk. Lymphoma 52(11), 2097-2104 (2011).
187. Chang JE, Seo S, Kim KM et al. Rituximab and CHOP chemotherapy plus GM-CSF for previously untreated diffuse large B cell lymphoma in the elderly: A Wisconsin oncology network study. Clin. Lymphoma Myeloma Leuk. 10(5), 379-384 (2010).
188. Olivieri A, Lucesole M, Capelli D et al. A new schedule of CHOP/rituximab plus granulocyte-macrophage colony-stimulating factor is an effective rescue for patients with aggressive lymphoma failing autologous stem cell transplantation. Biol. Blood Marrow Transplant. 11(8), 627-636 (2005).
189. Niitsu N, Hayama M, Okamoto M et al. Phase I study of rituximab-CHOP regimen in combination with granulocyte colony-stimulating factor in patients with follicular lymphoma. Clin. Cancer Res. 10(12 Pt 1), 4077-4082 (2004).
190. Cheng YC, Valero V, Davis ML et al. Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2 metastatic breast cancer patients. Br. J. Cancer 103(9), 1331-1334 (2010).
191. Ragnhammar P, Fagerberg J, Frodin JE et al. Effect of monoclonal antibody 17 1A and GM-CSF in patients with advanced colorectal carcinoma - long-lasting, complete remissions can be induced. Int. J. Cancer 53(5), 751-758 (1993).
192. Liljefors M, Nilsson B, Fagerberg J, Ragnhammar P, Mellstedt H, Frodin JE. Clinical effects of a chimeric anti-EpCAM monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma. Int. J. Oncol. 26(6), 1581-1589 (2005).
193. Kushner BH, Kramer K, Cheung NK. Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J. Clin. Oncol. 19(22), 4189-4194 (2001).
194. Liljefors M, Ragnhammar P, Nilsson B, Ullenhag G, Mellstedt H, Frodin JE. Anti-EpCAM monoclonal antibody (MAb17 1A) based treatment combined with a interferon, 5 fluorouracil and granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma. Int. J. Oncol. 25(3), 703-711 (2004).
195. Van Der Kolk LE, Grillo-Lopez AJ, Baars JW, Van Oers MH. Treatment of relapsed B cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G CSF: Final report on safety and efficacy. Leukemia 17(8), 1658-1664 (2003).
196. Khan KD, Emmanouilides C, Benson DM et al. A Phase 2 study of rituximab in combination with recombinant interleukin 2 for rituximab-refractory indolent non-Hodgkin's lymphoma. Clin. Cancer Res. 12(23), 7046-7053 (2006).
197. Eisenbeis CF, Grainger A, Fischer B et al. Combination immunotherapy of B cell non-Hodgkin's lymphoma with rituximab and interleukin 2: A preclinical and Phase I study. Clin. Cancer Res. 10(18 Pt 1), 6101-6110 (2004).
198. Repka T, Chiorean EG, Gay J et al. Trastuzumab and interleukin 2 in HER2-positive metastatic breast cancer: A pilot study. Clin. Cancer Res. 9(7), 2440-2446 (2003).
199. Fleming GF, Meropol NJ, Rosner GL et al. A Phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: Report of Cancer and Leukemia Group B 9661. Clin. Cancer Res. 8(12), 3718-3727 (2002).
200. Mani A, Roda J, Young D et al. A Phase II trial of trastuzumab in combination with low-dose interleukin 2 (IL 2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab. Breast Cancer Res. Treat. 117(1), 83-89 (2009).
201. Frost JD, Hank JA, Reaman GH et al. A Phase I/Ib trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin 2 in children with refractory neuroblastoma: A report of the children's cancer group. Cancer 80(2), 317-333 (1997).
202. Albertini MR, Hank JA, Schiller JH et al. Phase Ib trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients. Clin. Cancer Res. 3(8), 1277-1288 (1997).
203. Ansell SM, Geyer SM, Maurer MJ et al. Randomized Phase II study of interleukin 12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients. Clin. Cancer Res. 12(20 Pt 1), 6056-6063 (2006).
204. Parihar R, Nadella P, Lewis A et al. A Phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: Analysis of sustained interferon gamma production in a subset of patients. Clin. Cancer Res. 10(15), 5027-5037 (2004).
205. Bekaii-Saab TS, Roda JM, Guenterberg KD et al. A Phase I trial of paclitaxel and trastuzumab in combination with interleukin 12 in patients with HER2/ neu-expressing malignancies. Mol. Cancer Ther. 8(11), 2983-2991 (2009).